AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

Breast cancer often relapses in distant organs even when complete regression of primary tumors is achieved after initial ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...